More recently, new approaches using different ASM inhibitors or immunotherapy with antibodies against A-SMase were shown to alleviate AD pathology, however, these studies did not address the function of A-SMase in glial activation and the secretion of neurotoxic EVs [60, 61]. Here, SMPD1 is linked to Alzheimer disease.